



REMARKSRejection of claims under 35 U.S.C. 102:

Claims 6 has been rejected under 35 U.S.C. 102(b) as being anticipated by DE 1963399 A, compound RN 32797-22-1. Applicants have amended the claim to obviate the rejection. Specifically, the claim has been amended to claim a process for condensing a nucleic acid by forming a polymer from the indicated monomer in the presence of the nucleic acid. Support for the amendment can be found on page 7 line 2 to page 8 line 23, page 22 line 20 to page 24 line 20.

The Examiner's rejections are now believed to be overcome by this response to the Office Action. In view of Applicants' amendment and arguments, it is submitted that claims 6-8 should be allowable.

Respectfully submitted,


Mark K. Johnson Reg. No. 35,909
Mirus Bio Corporation
505 South Rosa Road
Madison, WI 53719
608-238-4400

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: 05/03/2005.

Kirk Ekena